Aspirin Per Se (i.e., 2-(acetyloxy)benozic Acid) Patents (Class 514/165)
-
Publication number: 20150072005Abstract: Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof. The methods entail orally administering to the subject a first composition comprising a first amount of aspirin, and a second composition comprising a second amount of aspirin, wherein the first composition is formulated so as to, upon administration, disintegrate or dissolve intraorally providing rapid release of the aspirin of the first composition in the subject, and wherein the second composition is formulated to be substantially more difficult than the first composition to disintegrate or dissolve intraorally but is ingestible and releasable in the gastrointestinal track of the subject. The method can further include administering to the subject a painkiller or an agent suitable for treating a cardiovascular disease or condition.Type: ApplicationFiled: September 10, 2013Publication date: March 12, 2015Inventor: Joseph P. Habboushe
-
Publication number: 20150072961Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: ApplicationFiled: November 14, 2014Publication date: March 12, 2015Inventors: Chongxi YU, Lina XU
-
Publication number: 20150051161Abstract: The present invention provides compositions and methods for detecting carboxymethyl-lysine (CML) and circulating receptor for advanced glycation end (RAGE) products, and methods for correlating CML and RAGE levels with age-related disease. In particular, serum CML and/or circulating receptor for advanced glycation end (RAGE) products can be used as a clinical biomarker in diagnostics to identify people who are at a higher risk of developing adverse ageing-related outcomes.Type: ApplicationFiled: April 10, 2014Publication date: February 19, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Richard David Semba, Luigi Ferruci, Edward G. Lakatta
-
Publication number: 20140370011Abstract: The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of cognitive disorders.Type: ApplicationFiled: September 4, 2014Publication date: December 18, 2014Applicant: DARA BIOSCIENCES, INC.Inventor: Mary Katherine Delmedico
-
Publication number: 20140356348Abstract: Described are methods for diagnosing and predicting the risk of pregnancy loss in a subject based on the presence of an aberrant humoral response to three proteins, Apolipoprotein B-100, alpha2macrogloblin (alpha2M), and fibronectin. The presence or a detectable level of maternal IgG antibodies to trophoblast-derived fibronectin and/or ApoB-100, and/or the absence or a non-detectable level of antibodies specifically binding to alpha2M is associated with a history of RPL and an increased risk of pregnancy loss. Also described are methods for identifying subjects at risk of pregnancy loss, selecting subjects for participation in a clinical study, and methods of decreasing the risk of pregnancy loss in a subject which include detecting the presence or absence of antibodies to one or more of trophoblast-derived ApoB-100, alpha2M, and fibronectin. Also provided are kits that contain ApoB-100, alpha2M, and fibronectin.Type: ApplicationFiled: May 13, 2014Publication date: December 4, 2014Applicant: University of Louisville Research Foundation, Inc.Inventors: Douglas D. Taylor, Cicek Gercel-Taylor
-
Publication number: 20140348818Abstract: Biomarkers of Kawasaki Disease (KD) are provided. In certain aspects, methods are provided for detecting KD biomarkers, such as elevated PDGFC expression. Likewise, methods of treating a subject having a biomarker of KD are described.Type: ApplicationFiled: December 21, 2012Publication date: November 27, 2014Inventors: Virginia M. Pascual, Zhaohui Xu, Octavio Ramilo, Rolando Cimaz
-
Publication number: 20140341988Abstract: Pharmaceutical dosage forms, particularly dosage forms in granular form having good palatability and capable of rapidly and completely dispersed in the mouth when orally administered.Type: ApplicationFiled: May 15, 2014Publication date: November 20, 2014Applicant: APR APPLIED PHARMA RESEARCH SAInventors: Alberto REINER, Giorgio REINER
-
Publication number: 20140335153Abstract: A method of preparing a thin film, the method comprising: (a) mixing a lipid, emulsifier, and solvent to provide a uniform first mixture; (b) contacting an active ingredient with the uniform first mixture to provide a thickened second mixture; (c) contacting a binder with the thickened second mixture to provide a slurry; and (d) hot extruding, casting, and condensing the slurry to provide the thin film; or cooling, shearing, mixing, casting, and condensing the slurry to provide the thin film.Type: ApplicationFiled: October 31, 2013Publication date: November 13, 2014Applicant: CURE Pharmaceutical CorporationInventors: Eric Allen, Robert Steven Davidson, Jose Bernardo
-
Publication number: 20140329779Abstract: The invention discloses a solid transparent vehicle utilizing DBS in which a topical pharmaceutical active or cosmetic active is solubilized without the use of a monohydric and/or polyhydric alcohol thus providing a non-tacky, clear solid, which prevents segregation and insures uniformity in dosing.Type: ApplicationFiled: January 22, 2013Publication date: November 6, 2014Applicant: PRODUCT AND TECHNOLOGY PARTNERS LLCInventors: Leonard Mackles, William Bess
-
Publication number: 20140328913Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.Type: ApplicationFiled: July 18, 2014Publication date: November 6, 2014Inventors: Roger A. Rinker, Nicholas J. Casale, James H. Comly, Brenda Pollack, Johan Geerke, Martin Costello, Dennis Wieand, Kishor Parekh
-
Publication number: 20140322328Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.Type: ApplicationFiled: July 24, 2013Publication date: October 30, 2014Applicant: OtiTopic, Inc.Inventor: Kambiz Yadidi
-
Patent number: 8871246Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.Type: GrantFiled: August 6, 2013Date of Patent: October 28, 2014Inventor: Lawrence Richard Bernstein
-
Patent number: 8865687Abstract: The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions: fraction a) consisting of long chain polyunsaturated fatty acids; fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine. fraction c) consisting of compounds which are a factor in methionine metabolism, which fraction contains at least one member selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.Type: GrantFiled: February 14, 2013Date of Patent: October 21, 2014Assignee: N.V. NutriciaInventors: Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
-
Publication number: 20140274975Abstract: The invention provides methods and compositions for diagnosing prior ischemic stroke or transient ischemic attack (TIA) and approximate the time said stroke occurred, comprising measurement of IgG and IgM antibodies to NR2A and/or NR2B NMDA receptor or fragment thereof in a biological sample, and comparing those measurements to reference population standards and to each other. The invention also includes optionally measuring other biomarkers for autoimmune disease for the reduction in false positives and better risk stratification for future stroke events. The method is particularly useful for identifying individuals that are at risk for future stroke or TIA, and for diagnosing previous history of ischemic stroke or TIA. This measurement and comparison enables determination of the risk of future stroke which is by definition higher in those patients who have suffered a previous stroke.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Health Diagnostic Laboratory, Inc.Inventors: Rebecca E. CAFFREY, Mohmed ASHMAIG
-
Patent number: 8834858Abstract: The present invention relates to compounds, and compositions, useful for treating dyslipidemia.Type: GrantFiled: July 1, 2011Date of Patent: September 16, 2014Assignee: Solvotrin Therapeutics Ltd.Inventors: Mark Ledwidge, Pat O'Flynn, John Gilmer
-
Publication number: 20140255342Abstract: Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the present application.Type: ApplicationFiled: May 19, 2014Publication date: September 11, 2014Applicants: TIANJIN HEMAY BIO-TECH CO., LTD., TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTDInventors: Hesheng Zhang, Guanghuai Zeng, Yifei Gao
-
Publication number: 20140248352Abstract: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated aspirin active ingredient, and preferably a lightly compressed matrix comprising directly compressible carbohydrate(s) and at least one sweetener.Type: ApplicationFiled: May 12, 2014Publication date: September 4, 2014Applicant: MCNEIL-PPC, INC.Inventors: Manoj N. Shah, James S. Beahm, Robert Shen
-
Publication number: 20140242161Abstract: The present invention relates to soft gelatin capsules characterized in that the shell includes a cyclodextrin and in that the filling material contains a liposoluble drug capable of forming a complex with said cyclodextrin for improving the solubility of the active ingredient upon disintegration of the soft gelatin capsule.Type: ApplicationFiled: April 7, 2014Publication date: August 28, 2014Inventors: Giorgio ZOPPETTI, Maurizio MARCHIORRI
-
Publication number: 20140242153Abstract: Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.Type: ApplicationFiled: January 30, 2014Publication date: August 28, 2014Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Raphael J. Mannino, Susan Gould-Fogerite, Sara L. Krause-Elsmore, David Delmarre, Ruying Lu
-
Publication number: 20140234284Abstract: The present invention relates to an isocyanate-free multi-component system, in particular for medical uses such as foamable wound coverings, with at least two separate components, wherein the first component comprises at least one alkoxysilane-terminated prepolymer and the second component comprises an aqueous component, wherein the aqueous component is a polyurethane dispersion.Type: ApplicationFiled: September 24, 2012Publication date: August 21, 2014Applicant: Bayer Intellectual Property GmbHInventors: Jan Schönberger, Sebastian Dörr
-
Patent number: 8809305Abstract: A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor.Type: GrantFiled: July 29, 2009Date of Patent: August 19, 2014Assignee: Galderma Research & DevelopmentInventors: Michael Graeber, Yin Liu, Barbara Gore
-
Patent number: 8802656Abstract: A new pharmaceutical composition is disclosed comprising a purified phospholipid-selective and/for nonselective non-steroidal, anti-inflammatory drug associated complex and methods for making and using same. A screening method for identifying compounds that form phospholipid associated complexes is also disclosed.Type: GrantFiled: October 12, 2005Date of Patent: August 12, 2014Assignee: The Board of Regents of the University of Texas SystemInventor: Lenard Lichtenberger
-
Patent number: 8802145Abstract: The invention relates to a method of manufacture of fast-disintegrating solid dosage forms, characterized in that one or more structure building components in mixed solid powder form are dosed into cavities of blister packs or moulds, the remaining components dissolved in water dosed and added to the powder to form a moistened, plasticized mass, frozen to below ?20° C., and the water sublimed in high vacuum. In this way solid dosage forms are obtained with a similar porous structure as usually result from freeze drying processes, but the process requires much less water, which means considerably less time and less energy.Type: GrantFiled: October 27, 2005Date of Patent: August 12, 2014Assignee: Pantec AGInventor: Kurt Heinz Bauer
-
Publication number: 20140206632Abstract: A method for determining the risk, severity or progression of cardiovascular disease, such as cardiac heart failure. A method for determining the likelihood of admission to the hospital for cardiac heart failure. The methods include determining the concentration of ET-1 and the concentration of one or more of biomarkers selected from the group consisting of cardiac troponin (e.g., cTnI, cTnT), VEGF, BNP, NT-proBNP, and IL-6 in a blood, serum or plasma sample from the patient.Type: ApplicationFiled: January 22, 2014Publication date: July 24, 2014Applicant: Singulex, Inc.Inventors: John Todd, Joel Estis, Victoria Torres
-
Patent number: 8785420Abstract: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).Type: GrantFiled: January 17, 2012Date of Patent: July 22, 2014Assignee: Galderma Research & DevelopmentInventors: Marie-Line Abou Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
-
Patent number: 8785421Abstract: Hydroxylated derivatives of vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol) are effective for preventing or treating mastitis in animals. The hydroxylated derivatives of vitamins D3 or D2 are administered to the mammary gland of a female animal in an amount effective to inhibit or significantly reduce the growth of bacteria in the animal's mammary gland.Type: GrantFiled: March 30, 2012Date of Patent: July 22, 2014Assignee: The United States of America as represented by the Secretary of AgricultureInventors: John D. Lippolis, Timothy A. Reinhardt
-
Publication number: 20140199232Abstract: Disclosure of methods and compositions related to chemical conjugations to nanoparticles of polysaccharides cross-linked to poloxamers as well as nano-sized colloids comprised of polysaccharides and poloxamers. The nanoparticles may be produced by various methods including inverse miniemulsion polymerization processes which create nanogels of desired size, shape, and stability for controlled therapeutic drug delivery, imaging, and theragnostic applications.Type: ApplicationFiled: July 16, 2013Publication date: July 17, 2014Applicant: NANODERM SCIENCES, INC.Inventors: Richard A. Winchurch, Roy R. Yeoman
-
Publication number: 20140187519Abstract: Provided herein are diagnostic markers and uses thereof for predicting if a subject is at risk of a major adverse event. In particular, one aspect provided herein relates to methods to determine if a subject is at risk of having a major adverse effect by measuring at least 2, or at least 3 of the biomarkers beta 2 microglobulin, c-reactive protein and cystatin C.Type: ApplicationFiled: December 3, 2013Publication date: July 3, 2014Applicant: The Board Of Trustees Of The Leland Stanford Junior UniversityInventors: John P. Cooke, Nicholas J. Leeper, Kevin Nead
-
Publication number: 20140186418Abstract: A method for repairing or replacing damaged tissue, or for providing post-surgical augmentation, comprising administering a pliable biocompatible material and a physiologically acceptable suspending agent to a patient is disclosed. Copolymers of unsubstituted acrylate and substituted acrylate are disclosed as pliable biocompatible materials.Type: ApplicationFiled: March 7, 2014Publication date: July 3, 2014Inventor: Ayman BOUTROS
-
Patent number: 8759325Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: February 21, 2012Date of Patent: June 24, 2014Assignee: The Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20140170068Abstract: In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction.Type: ApplicationFiled: March 12, 2012Publication date: June 19, 2014Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventors: Geoffrey M. Thiele, Daniel R. Anderson, Michael J. Duryee
-
Publication number: 20140162988Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: June 12, 2014Applicant: BIOCOPEA LIMITEDInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Publication number: 20140161791Abstract: The present invention provides for compositions and methods for diagnosing and treating Kawasaki disease. More specifically, the proteomes of patients with KD are enriched for the meprin A, filamin B, and filamin C, which serve as biomarkers (and potential therapeutic targets) for KD. Accordingly, detection of these biomarkers, using compositions and methods provided for herein, can inform the therapy delivered to the subject.Type: ApplicationFiled: April 13, 2012Publication date: June 12, 2014Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Alex Kentsis, Susan Kim, Hanno Steen
-
Publication number: 20140154236Abstract: Described here are devices and methods for treating one or more conditions or symptoms associated with a tonsil procedure. In some variations, a drug-releasing device may be at least partially delivered to one or more tonsillar tissues before, during, or after a tonsil procedure. In some variations, the drug-releasing device may be configured to be biodegradable. In other variations, the drug-releasing device may comprise one or more hemostatic materials or one or more adhesives. The drug-releasing device may be configured to release one or more drugs or agents, such as, for example, one or more analgesics, local anesthetics, vasoconstrictors, antibiotics, combinations thereof and the like.Type: ApplicationFiled: February 6, 2014Publication date: June 5, 2014Applicant: INTERSECT ENT, INC.Inventors: Jerome E. HESTER, Anthony J. ABBATE, Richard E. KAUFMAN, David C. GALE, Gail M. ZALER, Bin HUANG, Lisa EARNHARDT, Vijaykumar RAJASEKHAR
-
Publication number: 20140128355Abstract: A high concentration baclofen solution is provided suitable for therapeutic use in a medical setting. A high concentration solution of baclofen in multivalent physiological ion solution such as artificial cerebrospinal fluid is provided with concentrations of baclofen of 10 mg/ml. Artificial cerebrospinal fluid is particularly advantageous as a baclofen solvent. A medical package is also provided for baclofen delivery to patients suffering from spasticity.Type: ApplicationFiled: January 15, 2014Publication date: May 8, 2014Applicant: WAYNE STATE UNIVERSITYInventors: Jay M. Meythaler, Stephen M. Tuel
-
Publication number: 20140128354Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: BIOCOPEA LIMITEDInventors: Robin M. Bannister, John Brew
-
Patent number: 8703184Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent.Type: GrantFiled: March 20, 2013Date of Patent: April 22, 2014Assignee: Wellesley Pharmaceuticals, LLCInventor: David A. Dill
-
Publication number: 20140094439Abstract: Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.Type: ApplicationFiled: June 3, 2013Publication date: April 3, 2014Inventors: Upendra K. Marathi, Susann Edler Childress, Shaun L. Gammill, Robert W. Strozier
-
Patent number: 8685948Abstract: A method of treating rheumatoid arthritis using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.Type: GrantFiled: August 14, 2013Date of Patent: April 1, 2014Assignee: Theaprin Pharmaceuticals Inc.Inventors: Harry G. Brittain, Philip Felice
-
Publication number: 20140086910Abstract: The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of Alzheimer's diseases.Type: ApplicationFiled: August 29, 2013Publication date: March 27, 2014Applicant: DARA BIOSCIENCES, INC.Inventor: Mary Katherine Delmedico
-
Patent number: 8680081Abstract: The present invention provides methods and compositions for the prophylactic or targeted prophylactic treatment of migraine. In one embodiment a patient is regularly given a therapeutically effective amount of a combination of a cyclooxygenase-2 inhibitor and acetylsalicylic acid or active derivative, for prophylactic treatment of migraine. In another embodiment, a patient, at a time prior to a determined time window, is administered a therapeutically effective amount of a cyclooxygenase-2 inhibitor, either alone or in combination with acetylsalicylic acid or active derivative, to prevent or reduce migraine symptoms during the time window. Representative compositions include a cyclooxygenase-2 inhibitor and acetylsalicylic acid or salicylate salt.Type: GrantFiled: August 27, 2001Date of Patent: March 25, 2014Inventor: Peter Van Patten
-
Publication number: 20140072646Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.Type: ApplicationFiled: August 26, 2013Publication date: March 13, 2014Inventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
-
Patent number: 8658625Abstract: External preparations for treatment of painful skin wound having an analgesic activity which comprises acetylsalicylic acid or its pharmacologically acceptable salt as an active ingredient.Type: GrantFiled: February 16, 2004Date of Patent: February 25, 2014Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Yukiko Inamoto, Mitsuhiro Kawada, Akihiro Hasui, Kenichi Hattori
-
Publication number: 20140044784Abstract: Disclosed is a combined formulation for oral administration to treat cardiovascular disease, including (a) cholesterol lowering agent mini-tablet having a diameter of 7.5 mm or less, which contain a cholesterol lowering agent, a stabilizer thereof and a pharmaceutically acceptable excipient and have a coating layer on the surface thereof, and (b) antithrombotic agent mini-tablets or mini-pellets having a diameter of 7.5 mm or less, which contain an antithrombotic agent and a pharmaceutically acceptable excipient and include an enteric coating film on the surface thereof. This formulation can improve treatment compliance depending on a combination prescription, and is controlled so that the cholesterol lowering agent is released in the gastrointestinal tracts and the antithrombotic agent is released in the intestines, thus suppressing the reactions and the side-effects between the drugs, inducing synergic effects of these drugs in vivo, and achieving improved stability.Type: ApplicationFiled: March 14, 2012Publication date: February 13, 2014Applicant: BORYUNG PHARMACEUTICAL CO., LTDInventors: Je Hak Kim, Kyung Wan Nam, Ju Won Park
-
Publication number: 20140031291Abstract: Disclosed herein are methods for the diagnosis, detection, and treatment of cardiovascular disease and symptoms thereof in a subject. Disclosed herein are methods of diagnosing ischemic heart disease, non-ischemic heart disease, myocardial infarction, tachy-pacing induced non-ischemic heart disease, heart failure, and catecholaminergic-induced arrhythmia and symptoms thereof in a subject. Disclosed herein are methods of screening the efficacy of a pharmaceutical agent for treating cardiovascular disease and symptoms thereof in a subject.Type: ApplicationFiled: July 18, 2013Publication date: January 30, 2014Applicant: THE OHIO STATE UNIVERSITYInventors: Peter Mohler, Cynthia Carnes, Chenglong Li, Thomas Hund, Pui-Kai Li
-
Publication number: 20140024623Abstract: The invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.Type: ApplicationFiled: January 15, 2013Publication date: January 23, 2014Applicants: Celera Corporation, The Brigham and Women's Hospital, Inc.Inventors: Paul M. Ridker, Daniel Chasman, Dov Shiffman
-
Publication number: 20140024624Abstract: Methods for reducing blood clotting in a subject are provided, including methods to reduce the risk of and/or treat blot clotting pathologies. Also provided are compositions useful to reduce the risk or treat blood clotting pathologies.Type: ApplicationFiled: March 15, 2013Publication date: January 23, 2014Applicant: THE OHIO STATE UNIVERSITYInventors: Chandan K. Sen, Sashwati Roy, Savita Khanna, Cameron Rink
-
Publication number: 20140018331Abstract: The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided.Type: ApplicationFiled: August 7, 2013Publication date: January 16, 2014Applicant: IPCA Laboratories LimitedInventors: Ashok KUMAR, Nellithanath Thankachen Byju
-
Patent number: 8629127Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: November 28, 2012Date of Patent: January 14, 2014Assignee: The Regents of the University of OklahomaInventor: Richard F. Harty
-
Patent number: 8623847Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: May 3, 2012Date of Patent: January 7, 2014Assignee: The Regents of the University of OklahomaInventor: Richard F. Harty